Olanzapine

Generic Name: Olanzapine

Brand Names: Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀N_₄S

CAS Number: 132539-06-1

Unique Ingredient Identifier: N7U69T4SZR

Background: Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication: Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions: Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer

Phase 3

Terminated

Conditions: Nausea
Neoplasms

First Posted Date: 2005-07-29

Last Posted Date: 2012-01-19

Lead Sponsor: Alberta Health services

Target Recruit Count: 80

Registration Number: NCT00124930

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder

Phase 3

Completed

Conditions: Schizophrenia
Bipolar Disorder

First Posted Date: 2005-06-10

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 100

Registration Number: NCT00113594

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Moscow, Russian Federation

The Effects of Risperidone and Olanzapine on Thinking

Phase 4

Completed

Conditions: Schizophrenia
Psychotic Disorders

First Posted Date: 2005-04-15

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00108368

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

First Posted Date: 2005-02-11

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 600

Registration Number: NCT00103571

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rio Piedras, Puerto Rico

Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2005-01-07

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 600

Registration Number: NCT00100776

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician, Raleigh, North Carolina, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tacoma, Washington, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT-5-hours, EST), or speak with your personal physician, Clementon, New Jersey, United States

Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

Phase 1

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2004-10-22

Last Posted Date: 2006-07-19

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00094640

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Barcelona, Spain

Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2004-10-21

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 500

Registration Number: NCT00094549

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Saint Petersburg, Russian Federation

Olanzapine in Patients With Borderline Personality Disorder

Phase 3

Completed

Conditions: Borderline Personality Disorder

First Posted Date: 2004-09-27

Last Posted Date: 2006-07-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 300

Registration Number: NCT00091650

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Phase 4

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

First Posted Date: 2004-08-23

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 340

Registration Number: NCT00090012

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

Phase 1

Completed

Conditions: Schizophrenia

First Posted Date: 2004-08-18

Last Posted Date: 2006-07-20

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00089869

Locations: 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician., Chula Vista, California, United States
🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Irving, Texas, United States
🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.", San Antonio, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy